1.
Pathological and clinical data of the arrayed prostate cancers
| Parameter | No. of patients (%) | |
| Study cohort on TMA* | Biochemical relapse | |
| * Numbers do not always add up to 12,432 in different categories because of cases with missing data. AJCC, American Joint Committee on Cancer. | ||
| Follow-up | 11,152 | 2,769 (24.8%) |
| Mean/ median (month) | 64.4/60.0 | – |
| Age (years) | ||
| ≤ 50 | 323 | 81 (25.1%) |
| 51-59 | 2,696 | 705 (26.1%) |
| 60-69 | 6,528 | 1,610 (24.7%) |
| ≥ 70 | 1,498 | 370 (24.7%) |
| Pretreatment PSA (ng/mL) | ||
| < 4 | 1,585 | 242 (15.3%) |
| 4-10 | 7,480 | 1,355 (18.1%) |
| 10-20 | 2,412 | 737 (30.6%) |
| > 20 | 812 | 397 (48.9%) |
| pT stage (AJCC 2002) | ||
| pT2 | 8,187 | 1,095 (13.4%) |
| pT3a | 2,660 | 817 (30.7%) |
| pT3b | 1,465 | 796 (54.3%) |
| pT4 | 63 | 51 (81.0%) |
| Gleason grade | ||
| ≤ 3+3 | 2,297 | 230 (10.0%) |
| 3+4 | 6,679 | 1,240 (18.6%) |
| 3+4 Tertiary 5 | 433 | 115 (26.6%) |
| 4+3 | 1,210 | 576 (47.6%) |
| 4+3 Tertiary 5 | 646 | 317 (49.1%) |
| ≥ 4+4 | 416 | 348 (83.7%) |
| Quantitative Gleason | ||
| ≤ 3+3 | 2,735 | 230 (8.4%) |
| 3+4, ≤ 5% | 1,581 | 164 (10.4%) |
| 3+4, 6%-10% | 1,587 | 241 (15.2%) |
| 3+4, 11%-20% | 1,245 | 258 (20.7%) |
| 3+4, 21%-30% | 678 | 203 (29.9%) |
| 3+4 31%-49% | 533 | 177 (33.2%) |
| 3+4 Tertiary 5 | 379 | 107 (28.2%) |
| 4+3, 50%-60% | 445 | 183 (41.1%) |
| 4+3, 61%-80% | 380 | 186 (48.9%) |
| 4+3 > 80% | 88 | 53 (60.2%) |
| 4+3 Tertiary 5 | 520 | 265 (51.0%) |
| ≥ 4+4 | 416 | 235 (56.5%) |
| pN stage | ||
| pN0 | 6,970 | 1,636 (23.5%) |
| pN+ | 693 | 393 (56.7%) |
| Surgical margin | ||
| Negative | 9,990 | 1,848 (18.5%) |
| Positive | 2,211 | 853 (38.6%) |